• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 608
  • 324
  • 90
  • 60
  • 33
  • 32
  • 18
  • 16
  • 13
  • 9
  • 9
  • 6
  • 4
  • 2
  • 2
  • Tagged with
  • 1295
  • 566
  • 196
  • 186
  • 182
  • 153
  • 149
  • 136
  • 128
  • 126
  • 106
  • 102
  • 93
  • 92
  • 89
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
491

Význam genetických mutací u karcinomu prsu / The Role of Genetic Mutations in Breast Cancer

Šustr, Jan January 2022 (has links)
Introduction: About 5 - 10% of breast carcinomas are caused by genetic mutations. The most common genetic mutation that is involved in the development of this malignancy is a mutation in the tumor suppressor genes BRCA1/2 whose carriers have approximately a 70% lifetime risk of developing breast cancer. The prognosis of patients with BRCA1/2-asociated breast carcinoma, compared to patients with sporadic breast carcinoma is the subject of many studies with ambiguous results. Aim: The aim of the theoretical part of this work was to approach the issue of breast cancer and the most common genetic syndromes associated with it. In the practical part of this work a retrospective study was carried out in order to compare BRCA1/2 mutated breast cancer patients with non-mutated breast cancer patients in the tumor profile, methods of treatment and prognosis. Methods: We retrospectively analyzed the data of 134 patients who were tested for the presence of BRCA1/2 mutation at the Institute of Medical Genetics, University Hospital in Pilsen during the years 2013-2018 and at the same time were treated for early breast cancer at the University Hospital in Pilsen during the years 2000-2020. 32 patients were BRCA1 positive (24%), 10 BRCA2 positive (7%) and 92 without BRCA1/2 mutation (69%). The follow- up time was...
492

Papilární renální karcinom / Papillary Renal Cell Carcinoma

Procházková, Kristýna January 2018 (has links)
The Pilsen region suffers the highest incidence of kidney tumours worldwide. Approximately 240 new cases diagnosed as C64 (malignant renal tumours outside the pelvis) were recorded in this region of about 580,000 inhabitants in 2015. Clear renal cell carcinoma has long held first place as the most common tumour, with papillary renal cell carcinoma (pRCC) being the second most frequently operated kidney tumour at the Urology Department of the University Hospital in Pilsen. The 2016 WHO classification of kidney tumours recognizes officially only the stratification of pRCC to type 1 (pRCC1) and type 2 (pRCC2). Unfortunately, the current division does not correspond with knowledge derived from everyday practice. Most clinical trials involving pRCC do not differentiate between the subtypes, adhering only to the official type 1 and 2 divisions and the atypical papillary forms being excluded from their studies. We therefore have to face the question of whether the histological pRCC subtype affects the risk of recurrence, or death, in surgically treated patients. The aim of this dissertation work is to take into consideration also all other papillary types which differ from characterization of pRCC1 and pRCC2. The analyses of a group of patients with surgically treated and histologically verified pRCC at...
493

Variability of FEV and Criterion for Acute Pulmonary Exacerbation

Jenkins, Bradlee A., Glenn, L. Lee 01 October 2014 (has links) (PDF)
Excerpt: Morgan et al. (1) concluded that cystic fibrosis (CF) in children and adolescents with a high baseline forced expiratory volume (FEV1) were less likely to have a therapeutic intervention or slower rate of FEV1 decline after a single acute decline in FEV1 of 10%. This conclusion is not well supported due to the arbitrary criteria used for defining a pulmonary exacerbation, as explained below.
494

Myocardial Work Assessment for the Prediction of Prognosis in Advanced Heart Failure

Hedwig, Felix, Nemchyna, Olena, Stein, Julia, Knosalla, Christoph, Merke, Nicolas, Knebel, Fabian, Hagendorff, Andreas, Schoenrath, Felix, Falk, Volkmar, Knierim, Jan 04 April 2023 (has links)
Objectives: The aim of this study was to investigate whether echocardiographic assessment of myocardial work is a predictor of outcome in advanced heart failure. Background: Global work index (GWI) and global constructive work (GCW) are calculated bymeans of speckle tracking, blood pressuremeasurement, and a normalized reference curve. Their prognostic value in advanced heart failure is unknown. Methods: Cardiopulmonary exercise testing and echocardiography with assessment of GWI and GCW was performed in patients with advanced heart failure caused by ischemic heart disease or dilated cardiomyopathy (n = 105). They were then followed up repeatedly. The combined endpoint was all-cause death, implantation of a left ventricular assist device, or heart transplantation. Results: The median patient age was 54 years (interquartile range [IQR]: 48–59.9). The mean left ventricular ejection fraction was 27.8 ± 8.2%, the median NT-proBNP was 1,210 pg/ml (IQR: 435–3,696). The mean GWI was 603 ± 329 mmHg% and the mean GCW was 742 ± 363 mmHg%. The correlation between peak oxygen uptake and GWI as well as GCW was strongest in patients with ischemic cardiomyopathy (r = 0.56, p = 0.001 and r = 0.53, p = 0.001, respectively). The median follow-up was 16 months (IQR: 12–18.5). Thirty one patients met the combined endpoint: Four patients died, eight underwent transplantation, and 19 underwent implantation of a left ventricular assist device. In themultivariate Cox regression analysis, only NYHA class, NT-proBNP and GWI (hazard ratio [HR] for every 50 mmHg%: 0.85; 95% CI: 0.77–0.94; p = 0.002) as well as GCW (HR for every 50 mmHg%: 0.86; 95% CI: 0.79–0.94; p = 0.001) were identified as independent predictors of the endpoint. The cut-off value for predicting the outcome was 455 mmHg% for GWI (AUC: 0.80; p < 0.0001; sensitivity 77.4%; specificity 71.6%) and 530 mmHg% for GCW (AUC: 0.80; p < 0.0001; sensitivity 74.2%; specificity 78.4%). Conclusions: GWI and GCW are powerful predictors of outcome in patients with advanced heart failure.
495

Eftersläp av fakturering inom Bas-väg : - En fallstudie av Trafikverket / Backlog of invoicing within Bas-väg : - A case study of Trafikverket

Wegard, Elin, Gustavsson, Emma January 2022 (has links)
Abstract The purpose of the study is to identify the backlog in invoicing within BAS-väg and be able to identify what it is due to. Furthermore, we also want to study whether Trafikverkets structure affects the backlog of invoicing. The organization that has been studied is Trafikverket which is responsible for a large proportion of Sweden's total road network. The study is based on a qualitative method and the results of conducted interviews with semi-structured questions. The study illustrates explanations from six project managers at Trafikverket and two site managers at their contracting services within BAS-väg. Material from the informants have been studied in connection with the study's questions formulation and illustrate this based on four different themes. All the informants had to answer the same main questions, however, the explanations for the backlog of invoicing is varied. The results of the study illustrate the main reason why the backlog is due to the contractor's subcontractor's delaying invoicing. The second explanation given by both parties is that there are different combinations of resource shortage, for example lack of time, financial resources and lack of competence. The informants also believe that there are contributing negative factors within the authority that affect the invoicing process. Reasons described are lack of system programs, inadequate financial forecasting methods and tough requirements of verifications from preformed jobs. In summary, the study has helped to illustrate various explanations for why the invoicing backlog is significantly larger in the last two months of the year. Both Trafikverket and the contractors have arrangements that need to be taken in order for the entire invoicing process to be smoother and faster.
496

Gene-Based Risk Stratification for Cardiac Disorders in LMNA Mutation Carriers / ラミン遺伝子変異キャリアにおける遺伝子型を用いた心疾患リスクの層別化

Nishiuchi, Suguru 25 September 2023 (has links)
京都大学 / 新制・論文博士 / 博士(医学) / 乙第13568号 / 論医博第2294号 / 新制||医||1068(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 森田 智視, 教授 石見 拓, 教授 佐藤 俊哉 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM
497

A Novel Four-Gene Prognostic Signature for Prediction of Survival in Patients with Soft Tissue Sarcoma

Wu, Changwu, Gong, Siming, Osterhoff, Georg, Schopow, Nikolas 26 April 2023 (has links)
Soft tissue sarcomas (STS), a group of rare malignant tumours with high tissue heterogeneity, still lack effective clinical stratification and prognostic models. Therefore, we conducted this study to establish a reliable prognostic gene signature. Using 189 STS patients’ data from The Cancer Genome Atlas database, a four-gene signature including DHRS3, JRK, TARDBP and TTC3 was established. A risk score based on this gene signature was able to divide STS patients into a low-risk and a high-risk group. The latter had significantly worse overall survival (OS) and relapse free survival (RFS), and Cox regression analyses showed that the risk score is an independent prognostic factor. Nomograms containing the four-gene signature have also been established and have been verified through calibration curves. In addition, the predictive ability of this four-gene signature for STS metastasis free survival was verified in an independent cohort (309 STS patients from the Gene Expression Omnibus database). Finally, Gene Set Enrichment Analysis indicated that the four-gene signature may be related to some pathways associated with tumorigenesis, growth, and metastasis. In conclusion, our study establishes a novel four-gene signature and clinically feasible nomograms to predict the OS and RFS. This can help personalized treatment decisions, long-term patient management, and possible future development of targeted therapy.
498

Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial

Feistritzer, Hans-Josef, Desch, Steffen, Freund, Anne, Poess, Janine, Zeymer, Uwe, Ouarrak, Taoufik, Schneider, Steffen, de Waha-Thiele, Suzanne, Fuernau, Georg, Eitel, Ingo, Noc, Marko, Stepinska, Janina, Huber, Kurt, Thiele, Holger 20 April 2023 (has links)
Objectives: To analyze the use and prognostic impact of active mechanical circulatory support (MCS) devices in a large prospective contemporary cohort of patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Background: Although increasingly used in clinical practice, data on the efficacy and safety of active MCS devices in patients with CS complicating AMI are limited. Methods: This is a predefined subanalysis of the CULPRIT-SHOCK randomized trial and prospective registry. Patients with CS, AMI and multivessel coronary artery disease were categorized in two groups: (1) use of at least one active MCS device vs. (2) no active MCS or use of intra-aortic balloon pump (IABP) only. The primary endpoint was a composite of all-cause death or renal replacement therapy at 30 days. Results: Two hundred of 1055 (19%) patients received at least one active MCS device (n = 112 Impella®; n = 95 extracorporeal membrane oxygenation (ECMO); n = 6 other devices). The primary endpoint occurred significantly more often in patients treated with active MCS devices compared with those without active MCS devices (142 of 197, 72% vs. 374 of 827, 45%; p < 0.001). All-cause mortality and bleeding rates were significantly higher in the active MCS group (all p < 0.001). After multivariable adjustment, the use of active MCS was significantly associated with the primary endpoint (odds ratio (OR) 4.0, 95% confidence interval (CI) 2.7–5.9; p < 0.001). Conclusions: In the CULPRIT-SHOCK trial, active MCS devices were used in approximately one fifth of patients. Patients treated with active MCS devices showed worse outcome at 30 days and 1 year.
499

Prognostic Value of Different CMR-Based Techniques to Assess Left Ventricular Myocardial Strain in Takotsubo Syndrome

Stiermaier, Thomas, Busch, Kira, Lange, Torben, Pätz, Toni, Meusel, Moritz, Backhaus, Sören J., Frydrychowicz, Alex, Barkhausen, Jörg, Gutberlet, Matthias, Thiele, Holger, Schuster, Andreas, Eitel, Ingo 20 April 2023 (has links)
Cardiac magnetic resonance (CMR)-derived left ventricular (LV) global longitudinal strain (GLS) provides incremental prognostic information on various cardiovascular diseases but has not yet been investigated comprehensively in patients with Takotsubo syndrome (TS). This study evaluated the prognostic value of feature tracking (FT) GLS, tissue tracking (TT) GLS, and fast manual long axis strain (LAS) in 147 patients with TS, who underwent CMR at a median of 2 days after admission. Long-term mortality was assessed 3 years after the acute event. In contrast to LV ejection fraction and tissue characteristics, impaired FT-GLS, TT-GLS and fast manual LAS were associated with adverse outcome. The best cutoff points for the prediction of long-term mortality were similar with all three approaches: FT-GLS −11.28%, TT-GLS −11.45%, and fast manual LAS −10.86%. Long-term mortality rates were significantly higher in patients with FT-GLS > −11.28% (25.0% versus 9.8%; p = 0.029), TT-GLS > −11.45% (20.0% versus 5.4%; p = 0.016), and LAS > −10.86% (23.3% versus 6.6%; p = 0.014). However, in multivariable analysis, diabetes mellitus (p = 0.001), atrial fibrillation (p = 0.001), malignancy (p = 0.006), and physical triggers (p = 0.006) outperformed measures of myocardial strain and emerged as the strongest, independent predictors of long-term mortality in TS. In conclusion, CMR-based longitudinal strain provides valuable prognostic information in patients with TS, regardless of the utilized technique of assessment. Long-term mortality, however, is mainly determined by comorbidities.
500

The PLOD family: Novel biomarkers and potential therapy targets for personalized treatment in Soft Tissue Sarcoma

Gong, Siming 25 September 2023 (has links)
The Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase (PLOD) family contains three members: PLOD1, PLOD2 and PLOD3. The PLOD family catalyze the lysyl hydroxylase (LH) which plays a crucial role in the synthesis of collagen. As one of the most important components in ECM, collagen plays a crucial role in normal tissues. Soft tissue sarcomas (STS) are malignant tumors with more than 100 subtypes which origin from mesenchymal tissue. Although the STS is a rare malignancy accounting for less than 1% of all adult tumors, it has been reported to be responsible for 20% of all cancer-related deaths in childhood and adolescence. In this study, the relation between PLOD family and STS was analyzed. The overexpression of PLOD family is associated with poor prognosis and the PLOD family seems to be a regulator in TME. The PLOD family could serve as strong novel biomarkers and may be used as a therapy target for personalized treatment in STS.

Page generated in 0.0561 seconds